imipenem cilastatin/relebactam (Recarbrio)

From Aaushi
Jump to navigation Jump to search

Indications

* gram negative infections

Adverse effects

Drug interactions

More general terms

Components

References

  1. Brown T FDA Approves Drug Trio for UTI, Intra-abdominal Infection. Medscape - Jul 17, 2019. https://www.medscape.com/viewarticle/915723
    FDA News Release. July 17, 2019 FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections [press release]. Rockville, MD. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-complicated-urinary-tract-and-complicated-intra-abdominal-infections
  2. 2.0 2.1 FDA News Release. June 4, 2020 FDA Approves Antibiotic to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. https://www.fda.gov/news-events/press-announcements/fda-approves-antibiotic-treat-hospital-acquired-bacterial-pneumonia-and-ventilator-associated
  3. 3.0 3.1 Rapid Review Quiz: Hospital-Acquired Pneumonia Medscape. Sept 15, 2022 https://reference.medscape.com/viewarticle/980567
  4. HIGHLIGHTS OF PRESCRIBING INFORMATION imipenem, cilastatin & relebactam (Recarbrio) for injection, intravenous use https://www.merck.com/product/usa/pi_circulars/r/recarbrio/recarbrio_pi.pdf